Insights in Hodgkin Lymphoma angiogenesis

Leukemia Research

Volumn 38, Issue 8, 2014, Pages 857-861

  Marinaccio, Christian ^a   Nico, Beatrice ^a   Maiorano, Eugenio ^a   Specchia, Giorgina ^a   Ribatti, Domenico ^a,b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Anti angiogenesis; Hodgkin Lymphoma; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CD163 ANTIGEN; LENALIDOMIDE; PANOBINOSTAT; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VORINOSTAT;

ANTIANGIOGENIC THERAPY; DISEASE COURSE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS; ANTI-ANGIOGENESIS; HODGKIN LYMPHOMA; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; IMMUNOMODULATION; MACROPHAGES; MAST CELLS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904543564     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.05.023     Document Type: Review

References (49)

1. Ribatti D., Nico B., Crivellato E., Roccaro A.M., Vacca A. The history of the angiogenic switch concept. Leukemia 2007, 21:44-52.
2. Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon, France.
3. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826.
4. Doussis-Anagnostopoulou I.A., Talks K.L., Turley H., Debnam P., Tan D.C., Mariatos G., et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002, 197:677-683.
5. Gharbaran R., Goy A., Tanaka T., Park J., Kim C., Hasan N., et al. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. J Hematol Oncol 2013, 6:62.
6. Dewan M.Z., Watanabe M., Ahmed S., Terashima K., Horiuchi S., Sata T., et al. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. Cancer Sci 2005, 96:466-473.
7. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
8. Fusetti L., Pruneri G., Gobbi A., Rabascio C., Carboni N., Peccatori F., et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000, 60:2527-2534.
9. Mizuno H., Nakayama T., Miyata Y., Saito S., Nishiwaki S., Nakao N., et al. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 2012, 26:2269-2276.
10. Korkolopoulou P., Thymara I., Kavantzas N., Vassilakopoulos T.P., Angelopoulou M.K., Kokoris S.I., et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005, 19:894-900.
11. Citak E.C., Oguz A., Karadeniz C., Akyurek N. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract 2008, 204:89-96.
12. Kuittinen O., Soini Y., Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002, 69:205-212.
13. Teofili L., Di Febo A.L., Pierconti F., Maggiano N., Bendandi M., Rutella S., et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001, 97:1063-1069.
14. Passam F.H., Alexandrakis M.G., Kafousi M., Fotinou M., Darivianaki K., Tsirakis G., et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009, 205:11-20.
15. Bardelli M., Leucci E., Schurfeld K., Bellan C., Passiatore G., Rocchigiani M., et al. VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues. Leuk Lymphoma 2007, 48:2014-2021.
16. Khnykin D., Troen G., Berner J.M., Delabie J. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol 2006, 208:431-438.
17. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004, 28:595-604.
18. Rueda A., Olmos D., Villareal V., Torres E., Pajares B.I., Alba E. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma 2007, 7:400-405.
19. Okur F.V., Karadeniz C., Buyukpamukcu M., Oguz A., Yucel A., Cinaz P., et al. Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatr Blood Cancer 2010, 55:1272-1277.
20. Gille H., Kowalski J., Li B., LeCouter J., Moffat B., Zioncheck T.F., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001, 276:3222-3230.
21. Takahashi T., Yamaguchi S., Chida K., Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001, 20:2768-2778.
22. Dimtsas G.S., Georgiadi E.C., Karakitsos P., Vassilakopoulos T.P., Thymara I., Korkolopoulou P., et al. Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leuk Lymphoma 2014, 55:558-564.
23. Azambuja D., Natkunam Y., Biasoli I., Lossos I.S., Anderson M.W., Morais J.C., et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012, 23:736-742.
24. Kayal S., Mathur S., Karak A.K., Kumar L., Sharma A., Bakhshi S., et al. CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leuk Lymphoma 2014, 55:1031-1037.
25. Sanchez-Espiridion B., Martin-Moreno A.M., Montalban C., Medeiros L.J., Vega F., Younes A., et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012, 97:1080-1084.
26. Klein J.L., Nguyen T.T., Bien-Willner G.A., Chen L., Foyil K.V., Bartlett N.L., et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014, 141:381-387.
27. Koh Y.W., Park C.S., Yoon D.H., Suh C., Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLOS ONE 2014, 9:e87066.
28. Molin D., Edstrom A., Glimelius I., Glimelius B., Nilsson G., Sundstrom C., et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002, 119:122-124.
29. Glimelius I., Edstrom A., Fischer M., Nilsson G., Sundstrom C., Molin D., et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005, 19:2360-2362.
30. Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res 2007, 31:439-444.
31. Ribatti D., Nico B., Ranieri G., Specchia G., Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013, 15:231-238.
32. Yu D.D., Liu H.L., Bai Y.L., Wu B., Chen W.H., Ren J.H., et al. Correlation between increased circulating endothelial progenitor cells and stage of non-Hodgkin lymphoma. J Huazhong Univ Sci Technol Med Sci 2013, 33:284-287.
33. Ribatti D., Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 2005, 19:1525-1531.
34. Garcia-Sanz R., Gonzalez-Lopez T.J., Vazquez L., Hermida G., Graciani I.F., San Miguel J.F. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. Eur J Haematol 2010, 84:266-270.
35. Kuruvilla J., Song K., Mollee P., Panzarella T., McCrae J., Nagy T., et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006, 11:25-29.
36. Bartlett J.B., Michael A., Clarke I.A., Dredge K., Nicholson S., Kristeleit H., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004, 90:955-961.
37. Kotla V., Goel S., Nischal S., Heuck C., Vivek K., Das B., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
38. Fehniger T.A., Larson S., Trinkaus K., Siegel M.J., Cashen A.F., Blum K.A., et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011, 118:5119-5125.
39. Boll B., Borchmann P., Topp M.S., Hanel M., Reiners K.S., Engert A., et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010, 148:480-482.
40. Tempescul A., Ianotto J.C., Eveillard J.R., Guillerm G., Berthou C. ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Ann Hematol 2011, 90:971-973.
41. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
42. Blum K.A., Johnson J.L., Niedzwiecki D., Canellos G.P., Cheson B.D., Bartlett N.L. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313-1319.
43. Younes A., Pro B., Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006, 107:1731-1732.
44. Reiners K.S., Gossmann A., von Strandmann E.P., Boll B., Engert A., Borchmann P. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother 2009, 32:508-512.
45. Rasheed W., Bishton M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008, 8:413-432.
46. Kewitz S., Bernig T., Staege M.S. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. Leuk Res 2012, 36:773-778.
47. Kirschbaum M.H., Goldman B.H., Zain J.M., Cook J.R., Rimsza L.M., Forman S.J., et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012, 53:259-262.
48. Younes A., Sureda A., Ben-Yehuda D., Zinzani P.L., Ong T.C., Prince H.M., et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012, 30:2197-2203.
49. Lemoine M., Derenzini E., Buglio D., Medeiros L.J., Davis R.E., Zhang J., et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012, 119:4017-4025.